RayStation chosen for state-of-the-art proton and heavy ion center in Shanghai
Shanghai Proton and Heavy Ion Center (SPHIC) has chosen the innovative treatment planning system RayStation®* from RaySearch for its planned operations in the New Pudong district of Shanghai, the People's Republic of China. The parties will cooperate to achieve Chinese market clearance for proton and heavy ion treatment planning. The order is the first of its kind outside of Europe and Japan, where RaySearch is the market leader among comparable centers.
Already in clinical use at leading carbon ion therapy centers in Europe, RayStation has been chosen by China’s first proton and heavy ion center, SPHIC. The center operates the same Siemens-engineered proton and heavy ion treatment system in use in Europe. The decision was motivated by the outstanding functionality of RayStation and its comprehensive support for the proton and light ion treatment technique – as well as by its capacity to plan for photon linacs on the same software platform.
SPHIC will provide technical support and data for the RayStation regulatory submission process which will begin in 2020.
Carbon ion treatment planning in RayStation offers unique options to optimize personalized treatment plans along with proton and photon precision radiotherapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment.
The full RayStation installation includes modules for proton and carbon ion pencil beam scanning with robust biological optimization using both the local effect model and microdosimetric-kinetic models for radiobiological effect.
Johan Löf, CEO of RaySearch, says: “This order typifies the growing global interest in ways to consolidate treatment planning for diverse cancer treatment techniques and machines. All of us at RaySearch are thrilled to be chosen to meet the wide-ranging needs of such an important center in Shanghai and support its work at the forefront of cancer treatment in the region.”
The total order value is about 1.5 MEUR including service agreement, of which only a minor part is expected be recognized as revenues within the fourth quarter of 2019.
About SPHIC
Shanghai Proton and Heavy Ion Center, a.k.a. Proton and Heavy Ion Center of Fudan University Shanghai Cancer Center, is China’s first – the world’s third – proton and heavy ion center. Since its inauguration in May 2015, the center has achieved several milestones regarding the number of patients treated.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
About RayStation
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
* Subject to regulatory clearance in some markets, including China.
Latest news and RaySearch company information can be found at www.raysearchlabs.com
For further information, please contact:
Johan Löf, founder and CEO
Telephone: +46 (0)8-510 530 00
Peter Thysell, CFO
Telephone: +46 (0)70 661 05 59
